Cerevel Therapeutics Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CERE research report →
Companywww.cerevel.com
Cerevel Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety.
- CEO
- Ronald C. Renaud Jr.,
- IPO
- 2020
- Employees
- 355
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $8.19B
- P/E
- -16.83
- P/S
- 0.00
- P/B
- 10.81
- EV/EBITDA
- -18.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -72.44%
- ROIC
- -38.74%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-432,842,000 · -23.14%
- EPS
- $-2.67 · -15.09%
- Op Income
- $-447,265,000
- FCF YoY
- -16.48%
Performance & Tape
- 52W High
- $44.99
- 52W Low
- $19.59
- 50D MA
- $41.60
- 200D MA
- $38.67
- Beta
- 1.41
- Avg Volume
- 2.06M
Get TickerSpark's AI analysis on CERE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 24 | PFIZER INC | other | 27,349,211 |
| Aug 1, 24 | BAIN CAPITAL INVESTORS LLC | sell | 65,679,781 |
| Aug 1, 24 | Gordon Christopher R | sell | 3,282 |
| Aug 1, 24 | Gordon Christopher R | sell | 80,189 |
| Aug 1, 24 | Gordon Christopher R | sell | 65,679,781 |
| Aug 1, 24 | Gordon Christopher R | sell | 10,461 |
| Aug 1, 24 | Koppel Adam | sell | 3,282 |
| Aug 1, 24 | Koppel Adam | sell | 65,679,781 |
| Aug 1, 24 | Koppel Adam | sell | 10,461 |
| Aug 1, 24 | Koppel Adam | sell | 80,189 |
Our CERE Coverage
We haven't published any research on CERE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CERE Report →